Key facts
- This page summarizes David James Lennon's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2026, 16:03.
David James Lennon - 14 May 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- WHWK
- Reported as of
- 14 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 May 2026, 16:03:41 UTC
- Prior SEC filing
- 10 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Rodin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David James Lennon filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 18 May 2026.
Change
- Previous filing in this sequence was filed on 10 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001995275
Primary reporting owner
Lennon David James
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
- Signature
- /s/ Stephen Rodin, as Attorney-in-Fact
- Signature date
- 18 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WHWK
transaction
Common Stock
Award
- Transaction value
- Shares
- +51,021
- Change %
- +9.8%
- Price
- $3.92*
- Shares after
- 569,643
- Date
- 14 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.